Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/13993003.02327-2016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary lipoarabinomannan for diagnosis of Tuberculosis in an HIV-negative population: A scoping review.
Afr J Prim Health Care Fam Med
December 2024
Department of Internal Medicine, Prince Mshiyeni Memorial Hospital, Durban.
Background: Tuberculosis (TB) remains a leading cause of mortality in low-resource settings and poses a diagnostic challenge in human immunodeficiency virus (HIV)-negative populations because of limitations in traditional diagnostic methods such as sputum smear microscopy (SSM) and sputum Xpert Ultra. There is a lack of effective, non-invasive diagnostic options for TB diagnosis in HIV-negative populations. This scoping review explores the potential of urinary lipoarabinomannan (ULAM) as a point-of-care diagnostic tool for Mycobacterium tuberculosis (MTB) in HIV-negative individuals.
View Article and Find Full Text PDFEvaluation of the diagnostic efficiency of fluorescence hybridization for pulmonary tuberculosis: a systematic review and meta-analysis.
Front Med (Lausanne)
January 2025
Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Objective: In clinical practice, an accurate and efficient detection approach for pulmonary tuberculosis (PTB) is highly needed. The fluorescence hybridization (FISH) assay for PTB might be a suitable alternative to current tests. However, a systematic assessment of the diagnostic performance of this new approach is not available.
View Article and Find Full Text PDFDevelopment and Prospective Validation of a Novel Risk Score for Predicting the Risk of Poor Surgical Site Healing in Patients Following Surgical Procedure for Spinal Tuberculosis: A Multi-Center Cohort Study.
Surg Infect (Larchmt)
January 2025
Department of Nursing, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
The risk of poor surgical site healing in patients with spinal tuberculosis due to infection is known to be higher than in other surgical patients. Early identification and diagnosis are critical if we are to reduce the disability and mortality associated with spinal tuberculosis. We aimed to develop and validate a novel predictive score for predicting the risk of poor surgical site healing in patients following surgical procedure for spinal tuberculosis.
View Article and Find Full Text PDFEvaluation of extracts from used Xpert MTB/RIF cartridges for detection of resistance to second-line anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis in Ethiopia.
BMC Microbiol
January 2025
Mycobacteriology Research Center, Institute of Health, Jimma University, Jimma, Oromia, Ethiopia.
Background: Early and accurate diagnosis of drug resistance, including resistance to second-line anti-tuberculosis (TB) drugs, is crucial for the effective control and management of pre-extensively drug-resistant TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB). The Xpert MTB/XDR assay is the WHO recommended method for detecting resistance to isoniazid and second-line anti-TB drugs when rifampicin resistance is detected. Currently, the Xpert MTB/XDR assay is not yet implemented in Ethiopia, thus the MTBDRsl assay continues to be used.
View Article and Find Full Text PDFGenomic modifications for enhanced antibiotic production in rifamycin derivative-producing S699 strains: focusing on and genes.
Front Antibiot
June 2024
Institute of Pharmaceutical Biology and Biotechnology, Albert-Ludwigs-Universität, Freiburg, Germany.
Rifamycin and its derivatives are natural products that belong to the class of antibiotic-active polyketides and have significant therapeutic relevance within the therapy scheme of tuberculosis, a worldwide infectious disease caused by . Improving the oral bioavailability of rifamycin B was achieved through semisynthetic modifications, leading to clinically effective derivatives such as rifampicin. Genetic manipulation of the rifamycin polyketide synthase gene cluster responsible for the production of rifamycin B in the strain S699 represents a promising tool to generate new rifamycins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!